Everolimus Impurity
Write to us on the following email id to get specific quote venkat@veeprhopharma.com

Everolimus Impurity A

Everolimus Impurity

Welcome to Veeprho Pharmaceuticals s.r.o, manufacturer and supplier of Everolimus Impurities. We also offer other Everolimus based products, including Everolimus Impurity C (CAS No. 1062122-63-7), Everolimus Impurity D (Isomer 1 & 2) / Everolimus Retroaldol Degradation Product (CAS No. 1708118-13-1), Everolimus Impurity E / Ester hydrolysis degradant of IP D (CAS No. 147438-30-0), TGR / Everolimus tert-Butyldimethylsilyl Ether Impurity (CAS No. 159351-68-5), Everolimus Process Impurity, Everolimus Degradation Impurity, Everolimus Impurity and Everolimus Potential Impurity. We also undertake the manufacturing and supply of all Everolimus impurities mentioned above, which have to be isolated by preparative HPLC and Lyophilized.


On purchase of any of these impurities, you will receive a certificate of analysis and characterization data like NMR MASS IR and HPLC Purity. You can also request for receiving additional information like CHN, C NMR and TGA RF.


Veeprho Pharmaceuticals s.r.o also manufacture and supply Everolimus USP, EP, BP pharmacopoeia impurities, any unknown impurity, APIs and intermediates with structure elucidation with the help of H NMR, CHN, C NMR, MASS and HPLC data. We also provide all impurity of Everolimus as per to pharmacopoeia RRT if requested by the customers.


All regulatory agencies around the world including US-FDA, MCC, MHRA, WHO, Brazil and Japan accept the Everolimus impurities like Everolimus Impurity C (CAS No. 1062122-63-7), Everolimus Impurity D (Isomer 1 & 2) / Everolimus Retroaldol Degradation Product (CAS No. 1708118-13-1), Everolimus Impurity E / Ester hydrolysis degradant of IP D (CAS No. 147438-30-0), TGR / Everolimus tert-Butyldimethylsilyl Ether Impurity (CAS No. 159351-68-5) etc. are manufactured and supplied by Veeprho pharmaceuticals s.r.o. These Everolimus impurities are even used for genotoxic study as well as ANDA/DMF fillings.


Everolimus Impurities :-



Everolimus Impurity C
Everolimus Impurity C

(2S)-1-[2-Oxo-2-[(2R,3R,6S)-tetrahydro-2-hydroxy-6-[(2S,3E,5E,7E,9S,11R,13R,14R,15E, 17R,19E,21R)-14-hydroxy-22-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-2,13-dimethoxy-3,9,11,15,17,21-hexamethyl-12,18-dioxo-3,5,7,15,19-docosapentaen-1-yl]-3-methyl-2H-pyran-2-yl]acetyl]-2-piperidinecarb

Catalogue No : VL2280001

Everolimus Impurity D (Isomer 1 & 2) / Everolimus Retroaldol Degradation Product
Everolimus Impurity D (Isomer 1 & 2) / Everolimus Retroaldol Degradation Product

(S)-(2R,3S,6R,E)-1-((1S,3R,4R)-4-(2-Hydroxyethoxy )-3-methoxycyclohexyl)-2,6,8-trimethyl-5,9-diox onon-7-en-3-yl1-(2-((2R,3R,6S)-6-((2S,3E,5E,7E, 9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxotrideca-3,5,7-trien-1-yl)-2-hydroxy-3-methyl tetrahydro-2H-pyran-2-yl)-2-oxoacetyl)piperidine-2-carbox

Catalogue No : VL2280002

Everolimus Impurity E / Ester hydrolysis degradant of IP D
Everolimus Impurity E / Ester hydrolysis degradant of IP D

(2S)-1-[[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-Dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]tetrahydro-2-hydroxy-3-methyl-2H-pyran-2-yl]oxoacetyl]-2-piperidinecarboxylic Acid

Catalogue No : VL2280003

TGR / Everolimus tert-Butyldimethylsilyl Ether Impurity
TGR / Everolimus tert-Butyldimethylsilyl Ether Impurity

42-O-[2-[[(1,1-Dimethylethyl)dimethylsilyl]oxy] ethyl]rapamycin;23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontineRapamycin-Derivative

Catalogue No : VL2280004

Everolimus Impurity E
Everolimus Impurity E

(2S)-1-[[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-Dimethoxy-3,9,11-trimethyl-12- oxo-3,5,7-tridecatrienyl]tetrahydro-2-hydroxy-3-methyl-2H-pyran-2-yl]oxoacetyl]-2- piperidinecarboxylic Acid

Catalogue No : VL2280003